Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Southern African Journal of HIV Medicine

Field Value
Title Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
Creator Mahomed, Kairoonisha Wallis, Carole L. Dunn, Liezl Maharaj, Shavani Maartens, Gary Meintjes, Graeme
Subject — HIV drug resistance; antiretroviral therapy; regimens; dolutegravir; rifampicin
Description Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment-experienced patients unless there was prior use of a first-generation integrase inhibitor.Patient presentation: A 38-year-old woman diagnosed with tuberculosis was switched to a second-line antiretroviral regimen of zidovudine, lamivudine and dolutegravir 50 mg 12-hourly together with rifampicin-based TB treatment. Based on treatment history and a previous resistance test there was resistance to lamivudine but full susceptibility to zidovudine. The patient did not suppress her viral load on this regimen and later admitted to only taking dolutegravir 50 mg in the morning because of insomnia.Management and outcome: A second resistance test was performed which showed intermediate level of resistance to dolutegravir. Her regimen was changed to tenofovir, emtricitabine and ritonavir-boosted atazanavir with rifabutin replacing rifampicin for the remainder of her TB treatment. She achieved viral suppression on this regimen.Conclusion: To our knowledge this is the first case report from South Africa of emergent dolutegravir resistance in a treatment-experienced, integrase inhibitor-naïve patient. Factors that may have contributed to resistance emergence in this patient were that there was only one fully active nucleoside reverse transcriptase inhibitor in the regimen and lower exposure to dolutegravir because of the reduced dosing frequency while on rifampicin.
Publisher AOSIS
Date 2020-07-02
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajhivmed.v21i1.1062
Source Southern African Journal of HIV Medicine; Vol 21, No 1 (2020); 4 pages 2078-6751 1608-9693
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
Coverage — — —
Rights Copyright (c) 2020 Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes